1. Gupta AK, Paquet M, Villanueva E et al. Interventions for actinic keratoses.
Cochrane Database of Systematic Reviews issue 12: CD004415. 2012.
2. de Berker D, McGregor JM, Hughes BR: Guidelines for the management of actinic keratoses. Br J Dermatol 2007, 156(2):222-230.
3. M. NKUMNTSTHSIKWSI: Prevalence of actinic keratosis in Japan. Journal of Dermatological Science 1997, 15(3):183-187.
4. H. TPRCK: Dermatoscopy of flat pigmented facial lesions. . Journal of the European Academy of Dermatology & Venereology 2015, 29(1):120-127.
5. Filosa A, Filosa G: Actinic keratosis and squamous cell carcinoma: clinical and pathological features. G Ital Dermatol Venereol 2015, 150(4):379-384.
6. Keohane S, Kownacki S, Moncrieff G et al. PCDS Guidelines – Actinic (solar) keratosis: primary care treatment pathway. September 2012. [online] Available from
http://www.pcds.org.uk/ee/images/uploads/general/Actinic_(Solar)_Keratosis_
Primary_Care_Treatment_Pathway.pdf (Accessed March 22, 2016).
7. Dermatology referral and management pathway: solar (actinic) keratoses and Bowen's disease. [online] Available from
http://www.18weeks.scot.nhs.uk/patient-pathways/dermatology [Accessed March 21, 2016].
8. National Institute for Health and Clinical Excellence. NICE. Actinic keratosis:
ingenol mebutate gel. Evidence summary: new medicine. Published: 19 March 2013. Available from: nice.org.uk/guidance/esnm14 (Accessed March 21, 2016)
9. ATC/DDD Index 2016. WHO Collaborating Centre for Drug Statistics Methodology. http://www.whocc.no/atc_ddd_index/. Published 2016.
Accessed March 21, 2016.
10. 藥物許可證暨相關資料查詢作業網頁. 行政院衛生福利部食品藥物管理 署.
http://www.fda.gov.tw/MLMS/(S(dsxxi255g1grajigoqq0pz45))/H0001.aspx.
Accessed March 21, 2016.
11. 衛生福利部食品藥物管理署. 西藥、醫療器材、化粧品許可證查詢.
Available from:
http://www.fda.gov.tw/MLMS/(S(ejyfg32p1fuxjz55ywrqbl45))/H0001D.aspx?
Type=Lic&LicId=02024058 Accessed March 21, 2016.
12. 健保用藥品項查詢作業網頁. 行政院衛生福利部中央健康管理署
http://www.nhi.gov.tw/query/query1.aspx?menu=21&menu_id=713&webdata
_id=3510&WD_ID=851 Accessed March 28, 2016.
13. CADTH. Common Drug Review. CDEC FINAL RECOMMENDATION.
INGENOL MEBUTATE. Indication: Actinic Keratosis. Available from:
https://www.cadth.ca/ingenol-mebutate-11 (Accessed March 21, 2016) 14. PBAC. Ingenol Mebutate 0.015% gel, 3 x 470 mg tubes, Picato® - November
2013. Available from:
http://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/psd/2013-11/ingenol-mebutate (Accessed March 21, 2016)
15. PBAC. Ingenol Mebutate 0.015% gel, 3 x 470 mg tubes, Picato® - July 2014.
Available from:
http://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/psd/2014-07/ingenol-mebutate-psd-07-2014 (Accessed March 21, 2016)
16. Lebwohl M, Swanson N, Anderson LL, Melgaard A, Xu Z, Berman B: Ingenol Mebutate Gel for Actinic Keratosis. New England Journal of Medicine 2012, 366(11):1010-1019.
17. Scottish Medicines Consortium (SMC) Drug ID: 851/13; Manufacturer: LEO Pharmaceuticals; Indication: Cutaneous treatment of non-hyperkeratotic, non-hypertrophic actinic keratosis in adults. ; Submission Type: Full
submission; Status: Accepted; Date Advice Published: 11/03/2013; Available from:
https://www.scottishmedicines.org.uk/SMC_Advice/Advice/851_13_ingenol_
mebutate_gel_Picato/ingenol_mebutate_gel_Picato (Accessed March 30, 2016).
18. European Medicines Agency. Assessment Report – Picato EMA/650464/2012.
[online] Available from: www.ema.europa.eu (Accessed March 30, 2016).
19. Stein Gold L, Larsson T, Melgaard A. Long-term follow-up studies of ingenol mebutate gel for the treatment of actinic keratosis. American Academy of Dermatology Annual Meeting 2012 Poster Presentation #5620. 2012. [online]
Available from www.aad.org/Posters/view/default.aspx (Accessed March 30, 2016).
20. Ingenol Mebutate (Picato): Topical Treatment of Non-hyperkeratotic, Non-hypertrophic Actinic Keratosis in Adults [Internet]. Ottawa (ON):
Canadian Agency for Drugs and Technologies in Health; 2014 Feb.
Available from: http://www.ncbi.nlm.nih.gov/books/NBK195575/ (Accessed March 28, 2016).
21. Garbe C, Basset-Seguin N, Poulin Y, Larsson T, Osterdal ML, Venkata R, Lear JT: Efficacy and safety of follow-up field treatment of actinic keratosis with ingenol mebutate 0.015% gel: a randomized, controlled 12-month study. Br J
Dermatol 2016, 174(3):505-513.
22. Samorano LP, Torezan LA, Sanches JA: Evaluation of the tolerability and safety of a 0.015% ingenol mebutate gel compared to 5% 5-fluorouracil cream for the treatment of facial actinic keratosis: a prospective randomized trial. J Eur Acad Dermatol Venereol 2015, 29(9):1822-1827.
23. Szeimies RM: A network meta-analysis of the relative efficacy of treatments for actinic keratosis of the face or scalp in Europe. J Eur Acad Dermatol Venereol 2015.
24. Gupta AK, Paquet M: Network meta-analysis of the outcome 'participant complete clearance' in nonimmunosuppressed participants of eight
interventions for actinic keratosis: a follow-up on a Cochrane review. Br J Dermatol 2013, 169(2):250-259.
25. Ingenol, gel, 0.15 mg per g (0.015%), 70 mcg ingenol mebutate in 0.47 g single use tubes, 3, Picato® -November 2012 Available from:
http://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/psd/2012-11/ingenol (Accessed March 21, 2016)
26. AWMSG Secretariat Assessment Report Ingenol mebutate (Picato® ) 150 micrograms/g gel and 500 micrograms/g gel
[http://www.awmsg.org/awmsgonline/app/appraisalinfo/1392]
27. Soini EJ, Hallinen T, Sokka A-L, Saarinen K: Cost–Utility of First-Line Actinic Keratosis Treatments in Finland. Advances in therapy 2015, 32(5):455-476.
28. Tolley K, Kemmett D, Thybo S, Nasr R, Smethurst H: A cost-utility analysis of ingenol mebutate gel for the treatment of actinic keratosis: a Scottish perspective. The European Journal of Health Economics 2015:1-18.
29. Dodds A, Chia A, Shumack S: Actinic keratosis: rationale and management.
Dermatology and therapy 2014, 4(1):11-31.
30. Frost C, Green A: Epidemiology of solar keratoses. British Journal of Dermatology 1994, 131(4):455-464.
31. Holmes C, Foley P, Freeman M, Chong AH: Solar keratosis: epidemiology, pathogenesis, presentation and treatment. Australasian journal of dermatology 2007, 48(2):67-76.
32. Marks R, Ponsford M, Selwood T, Goodman G, Mason G: Non-melanotic skin cancer and solar keratoses in Victoria. The Medical journal of Australia 1982, 2(12):619-622.
33. Araki K, Nagano T, Ueda M, Washio F, Watanabe S, Yamaguchi N, Ichihashi M: Incidence of skin cancers and precancerous lesions in Japanese risk factors and prevention. Journal of Epidemiology 1999, 9(6sup):14-21.
34. 林栗伃, 許漢銘: 日光性角化症流行病學及台灣盛行率探討. 台灣皮膚科 醫學會第 40 屆年會暨學術研討會-光癌化機轉與日光性角化症之診斷、治 療及預防 2014:8-9.
35. Liao Y, Chen K, Tseng M, Sun C: Pattern of skin diseases in a geriatric patient group in Taiwan: a 7-year survey from the outpatient clinic of a university medical center. Dermatology 2001, 203(4):308-313.
36. Garbe C, Basset‐Seguin N, Poulin Y, Larsson T, Ø sterdal M, Venkata R, Lear J:
Efficacy and safety of follow‐up field treatment of actinic keratosis with ingenol mebutate 0· 015% gel: a randomized, controlled 12‐month study.
British Journal of Dermatology 2016.
附錄一 療效評估文獻搜尋記錄
資料庫 查詢日期 關鍵字 篩選後篇數
PubMed/EMBASE 2016.03.01
#1
picato or ingenol mebutate or PEP005 or "PEP 005" or ingenol angelate or ingenol 3 angelate or 3- Angeloylingenol or Euphorbia factor An1 or Euphorbia factor H1
169
#2 #1 and randomized 22 Total potentially relevant
reports identified and screened and reports included
7